GLP-1 misuse linked to serious harm in people with eating disorders: study

X Facebook WhatsApp

A new study in JAMA Psychiatry raises fresh concerns about how people with eating disorders are using GLP‑1 weight‑loss drugs such as Ozempic and Wegovy, suggesting these medications may be more commonly used — and misused — within this group than previously recognized. With prescriptions rising nationwide, clinicians warn the trend has immediate clinical implications for diagnosis, monitoring, and patient safety.

Researchers surveyed 436 people with diagnosed eating disorders and found that roughly one‑third reported ever using a GLP‑1 medication. About 22 percent were actively taking one at the time of the study, and just over 10 percent acknowledged behaviors the authors classified as misuse.

What the study measured and why it matters now

The study’s timing matters because GLP‑1 medications have moved rapidly from specialist care into mainstream prescribing for obesity and diabetes. That expansion increases the chance these drugs will reach patients whose disorders could be worsened by appetite‑suppressing treatments.

The investigators did not say GLP‑1 drugs are inherently unsafe, but they emphasized that powerful appetite‑reducing agents can have unintended harms when used by people with active or past eating disorders — including worsening malnutrition and medical instability.

How the study defined misuse

“Misuse” in the survey covered several behaviors clinicians regard as risky. Respondents who reported one or more of the following were counted as misusing a GLP‑1 medication:

Taking doses different from those prescribed, including increasing dose too quickly

Continuing use beyond medical guidance or without follow‑up care

Sharing injectable medication or tampering with injection supplies

Using compounded or less‑regulated formulations instead of a prescribed product

About one in ten participants said they had used compounded or otherwise less‑regulated GLP‑1 products, a practice that raises additional safety alarms around dosing accuracy and sterility.

Clinical consequences and practical risks

For people with restrictive eating disorders, appetite suppression and rapid weight loss can mask or intensify underlying pathology. That puts patients at risk for electrolyte imbalances, cardiac complications, and worsening psychiatric symptoms tied to disordered eating.

Even when a GLP‑1 drug treats a legitimate metabolic condition, the study’s authors argue that prescribing without a careful screen for eating‑disorder history may unintentionally reinforce harmful behaviors. In other words, context matters as much as the medicine itself.

What physicians and systems are doing

Some clinicians are already calling for routine screening for eating disorders before starting GLP‑1 therapy, and for closer monitoring during treatment. That approach would aim to identify patients who need coordinated care — medical oversight plus mental‑health and nutrition support — rather than standalone pharmacotherapy.

Policy and practice responses could include:

Standardized screening questionnaires in primary care and weight‑management clinics

Clear referral pathways to eating‑disorder specialists

Regular follow‑up to monitor nutrition, labs, and mental‑health status

These steps would help ensure that patients who can benefit from GLP‑1 medications receive them safely, while those at risk of harm get alternative or additional care.

Looking ahead

The study adds to a growing conversation about how to balance the clear metabolic benefits of GLP‑1 drugs with the potential for harm in vulnerable populations. Clinicians, health systems, and payers will need to weigh screening and monitoring costs against patient safety concerns as use of these medications continues to expand.

For patients and families, the practical takeaway is straightforward: disclose any history of disordered eating when discussing weight‑loss or diabetes medications, and expect clinicians to ask targeted questions before prescribing. Better screening and coordinated care can reduce the risk that a helpful treatment becomes harmful.